Regulation of vasodilator synthesis during lung development

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The endothelium-derived vasodilator molecules prostaglandin I2 (PGI2) and nitric oxide (NO) are critically involved in the dramatic increase in pulmonary blood flow that occurs during cardiopulmonary transition at birth. Studies in animal and cell culture models have revealed that there is increased PGI2 and NO production in the pulmonary circulation of the late fetus in direct response to increased oxygenation, and that this response is unique to the pulmonary endothelium. Additional work has demonstrated that there is normally marked upregulation in the expression of the key synthetic enzymes cyclooxygenase type 1 and endothelial NO synthase in the lung during late gestation, thereby maximizing the capacity for vasodilator production at the time of birth. Furthermore, studies in animal models of neonatal pulmonary hypertension indicate that attenuated expression of these genes may frequently contribute to the pathogenesis of the disorder. A greater understanding of the mechanisms regulating PGI2 and NO synthesis in the developing lung will potentially lead to novel therapies for neonatal pulmonary hypertension aimed at optimizing endogenous vasodilator production. Copyright (C) 1999 Elsevier Science ireland Ltd.

Original languageEnglish (US)
Pages (from-to)271-294
Number of pages24
JournalEarly Human Development
Volume54
Issue number3
DOIs
StatePublished - Apr 1 1999

Fingerprint

Vasodilator Agents
Epoprostenol
Lung
Nitric Oxide
Pulmonary Hypertension
Endothelium
Parturition
Cyclooxygenase 1
Pulmonary Circulation
Nitric Oxide Synthase Type III
Ireland
Fetus
Up-Regulation
Animal Models
Cell Culture Techniques
Gene Expression
Pregnancy
Enzymes
Therapeutics

Keywords

  • Cardiopulmonary transition
  • Lung development
  • Nitric oxide
  • Prostaglandin I
  • Vasodilator synthesis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Regulation of vasodilator synthesis during lung development. / Shaul, Philip W.

In: Early Human Development, Vol. 54, No. 3, 01.04.1999, p. 271-294.

Research output: Contribution to journalArticle

@article{c96ff4958e914704a658f649a2b18fe9,
title = "Regulation of vasodilator synthesis during lung development",
abstract = "The endothelium-derived vasodilator molecules prostaglandin I2 (PGI2) and nitric oxide (NO) are critically involved in the dramatic increase in pulmonary blood flow that occurs during cardiopulmonary transition at birth. Studies in animal and cell culture models have revealed that there is increased PGI2 and NO production in the pulmonary circulation of the late fetus in direct response to increased oxygenation, and that this response is unique to the pulmonary endothelium. Additional work has demonstrated that there is normally marked upregulation in the expression of the key synthetic enzymes cyclooxygenase type 1 and endothelial NO synthase in the lung during late gestation, thereby maximizing the capacity for vasodilator production at the time of birth. Furthermore, studies in animal models of neonatal pulmonary hypertension indicate that attenuated expression of these genes may frequently contribute to the pathogenesis of the disorder. A greater understanding of the mechanisms regulating PGI2 and NO synthesis in the developing lung will potentially lead to novel therapies for neonatal pulmonary hypertension aimed at optimizing endogenous vasodilator production. Copyright (C) 1999 Elsevier Science ireland Ltd.",
keywords = "Cardiopulmonary transition, Lung development, Nitric oxide, Prostaglandin I, Vasodilator synthesis",
author = "Shaul, {Philip W.}",
year = "1999",
month = "4",
day = "1",
doi = "10.1016/S0378-3782(98)00103-0",
language = "English (US)",
volume = "54",
pages = "271--294",
journal = "Early Human Development",
issn = "0378-3782",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Regulation of vasodilator synthesis during lung development

AU - Shaul, Philip W.

PY - 1999/4/1

Y1 - 1999/4/1

N2 - The endothelium-derived vasodilator molecules prostaglandin I2 (PGI2) and nitric oxide (NO) are critically involved in the dramatic increase in pulmonary blood flow that occurs during cardiopulmonary transition at birth. Studies in animal and cell culture models have revealed that there is increased PGI2 and NO production in the pulmonary circulation of the late fetus in direct response to increased oxygenation, and that this response is unique to the pulmonary endothelium. Additional work has demonstrated that there is normally marked upregulation in the expression of the key synthetic enzymes cyclooxygenase type 1 and endothelial NO synthase in the lung during late gestation, thereby maximizing the capacity for vasodilator production at the time of birth. Furthermore, studies in animal models of neonatal pulmonary hypertension indicate that attenuated expression of these genes may frequently contribute to the pathogenesis of the disorder. A greater understanding of the mechanisms regulating PGI2 and NO synthesis in the developing lung will potentially lead to novel therapies for neonatal pulmonary hypertension aimed at optimizing endogenous vasodilator production. Copyright (C) 1999 Elsevier Science ireland Ltd.

AB - The endothelium-derived vasodilator molecules prostaglandin I2 (PGI2) and nitric oxide (NO) are critically involved in the dramatic increase in pulmonary blood flow that occurs during cardiopulmonary transition at birth. Studies in animal and cell culture models have revealed that there is increased PGI2 and NO production in the pulmonary circulation of the late fetus in direct response to increased oxygenation, and that this response is unique to the pulmonary endothelium. Additional work has demonstrated that there is normally marked upregulation in the expression of the key synthetic enzymes cyclooxygenase type 1 and endothelial NO synthase in the lung during late gestation, thereby maximizing the capacity for vasodilator production at the time of birth. Furthermore, studies in animal models of neonatal pulmonary hypertension indicate that attenuated expression of these genes may frequently contribute to the pathogenesis of the disorder. A greater understanding of the mechanisms regulating PGI2 and NO synthesis in the developing lung will potentially lead to novel therapies for neonatal pulmonary hypertension aimed at optimizing endogenous vasodilator production. Copyright (C) 1999 Elsevier Science ireland Ltd.

KW - Cardiopulmonary transition

KW - Lung development

KW - Nitric oxide

KW - Prostaglandin I

KW - Vasodilator synthesis

UR - http://www.scopus.com/inward/record.url?scp=0032966380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032966380&partnerID=8YFLogxK

U2 - 10.1016/S0378-3782(98)00103-0

DO - 10.1016/S0378-3782(98)00103-0

M3 - Article

C2 - 10321793

AN - SCOPUS:0032966380

VL - 54

SP - 271

EP - 294

JO - Early Human Development

JF - Early Human Development

SN - 0378-3782

IS - 3

ER -